ANNA-BIOSCIENCES
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 15:00:00 CET | Press release
New release brings predictive intelligence, regional expansion, and enhanced employee performance tools to contact center operations. Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced al
FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler18.11.2025 15:00:00 CET | Press release
Deep Illumio integration and continued VMware NSX and Zscaler support, security teams can now operationalize Zero Trust at enterprise scale. FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler. By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale. “The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.” Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and
Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy18.11.2025 15:00:00 CET | Press release
Multi-year strategic partnership empowers Silicon Labs to maximize SAP ECC 6.0 value, accelerate transformation and avoid costly upgrades and disruption Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Silicon Labs has selected Rimini Street as its strategic partner to maximize the value of its SAP ECC 6.0 investment. This collaboration provides the U.S.-based semiconductor manufacturer with long-term SAP maintenance and professional services to accelerate modernization without costly upgrades or business disruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118277544/en/ Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy Partnership Reduces Technical Debt and Accelerates Modernization Sili
Gurobi Releases Version 13.0 with Improved Performance and New Solving Capabilities18.11.2025 15:00:00 CET | Press release
Users can expect faster solves, new nonlinear capabilities, PDHG with GPU acceleration, and Kubernetes autoscaling. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce the release of Gurobi 13.0. This latest version represents a significant advancement in Gurobi’s mission to help organizations tackle increasingly complex optimization challenges with greater speed and flexibility. Version 13.0 introduces performance improvements across core model types, new algorithm support for large-scale and nonlinear problems, GPU acceleration, and expanded cloud-native functionality. “Today’s organizations face optimization challenges that are often domain-specific and more complex than ever,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “With Gurobi 13.0, we’re extending our technology to handle even larger models and more nonlinear problem types—delivering measurable speed-ups and greater flexibility across a wide range of applications.” Enhancem
Core42 “Maximus-384” Cluster Secures Top 20 Ranking on the Global TOP500 Supercomputers List18.11.2025 14:24:00 CET | Press release
Core42, A G42 Company, secures #20 position with its AMD Instinct MI300X GPU cluster in Buffalo, New York.Results announced ahead of Supercomputing 2025.Collaboration between Core42, Broadcom and Arista Networks delivers a top performing and reliable HPC network with fast data transfers and minimal latency. Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced that itsMaximus-384 supercomputer has been ranked No. 20 globally on the TOP500 List, the industry’s most recognized benchmark for publicly known supercomputing systems. The ranking highlights the performance of the AMD Instinct™ MI300X GPU-based “Maximus” cluster, operated at the company’s facility in Buffalo, New York and released ahead of Supercomputing 2025, the leading global conference for HPC. The TOP500 list tracks performance trends across the global supercomputing systems using the High Performance Linpack benchmark (HPL) benchmark. Securing a top-20 position reflects exceptional enginee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom